{"id":959412,"date":"2026-05-06T21:18:32","date_gmt":"2026-05-07T01:18:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/"},"modified":"2026-05-06T21:18:32","modified_gmt":"2026-05-07T01:18:32","slug":"scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>JERSEY CITY, N.J., May  06, 2026  (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (Nasdaq: SCYX) (\u201cSCYNEXIS\u201d or the \u201cCompany\u201d), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company\u2019s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee\u2019s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The awards were granted pursuant to SCYNEXIS\u2019 2015 Inducement Award Plan, as amended, which was adopted by the Company\u2019s Board of Directors in March 2015 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.<\/p>\n<p>The inducement awards consist of stock options to purchase 125,000 shares of the Company\u2019s common stock at a per share exercise price of $0.93, the closing price per share of the Company\u2019s common stock as reported by Nasdaq on April 30, 2026, and restricted stock units (\u201cRSUs\u201d) covering 20,000 shares of the Company\u2019s common stock. The employee\u2019s stock options have a vesting commencement date of April 13, 2026, vest over a four-year period, with 25% of the shares underlying the option vesting on the on-year anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments thereafter over 36 months, subject to the employee\u2019s continued service with the Company. The employee\u2019s RSUs have a vesting commencement date of June 15, 2026, and vest in three equal annual installments over a three-year period, subject to the employee\u2019s continued service through each applicable vesting date.<\/p>\n<p>\n        <strong>About SCYNEXIS, Inc. <\/strong>\n      <\/p>\n<p>SCYNEXIS, Inc. (NASDAQ: SCYX) is dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS\u2019s proprietary antifungal platform \u201cfungerps\u201d includes BREXAFEMME<sup>\u00ae<\/sup> (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GOwPla6O3UrIQTjNK7oQp0tK9rvlVB_xRl8P_oIwD_UUycu3LzBdGTiMOBaetKVRwOZc09hGzPWyydAGf7cwmmhX4OXd7tB8PAa_cJOSoEBer7uDlEW8p8Z0tBzZwteIrHx95vf37MJHq6bIjDY1Gm-2f-hkunNe_lG7eBLnCn2NSyH_z0HteMrg_gjL-WCOmiWeckyfngCSNpQ66NBSnVEXy8IOgHBmueoP9Z30ZRHGtcaShnRxv3ZoBKdPOmdybB_ogqqC-vjKaKyx73UBvB7dDzYzeHfbffVlTijDFqOYgEkI88vK4ph6sHHyoDnjsvBxSe8wr2L_MQTPq9uFHHz7XrwzmUjJGlOQxcELWR860vffHJm3F1qT-XtGuD9lcYmRTVp38aD0DFHdwFbbhRv7Sx1dUyP-dPkMOMBjHjCbEtdWj1-lcrTItT0MeFZTAZ4Dfn0D8am_M72_UvlOqqYq_AwrHMaorlfLKWZNDeyccva8HTqVy29E3x0fncftkFmkJWk3V5GOQOyewqJvCTVwC3CLGE2BUwpL-ve3aRPvpnAmKbom1dW61dbBOZD6nQgwpUFhyqykt5c60OqlfYulmE7KklY4kPIpFGnKCJJMxC_EF8u2bRg8DImzwNm1n8iFjvGmYgkCAOGzOWSi1NwSlGBNnhwNV6t_dkR5UJv_EMwFivLsjbP6C84oglAPNcx8R9gL-nqOo-E-RXv-kxwMMGlCKE-3JuAlnxW-B3ZzXjco8Xdcyg8hrY7nvReozJAGmOGZsz1S1_ztE7T5fRGxtudP4n65Hu3XFrhnThamMKjY6IUm8HDoaqi0hPz51zaZhTzShCNd0Eh-vYDkENsTuys4t7opgKKX8VKujx6EzM7yl-WVg1--b_HqqNTDj_yOWLH-qTVAQjCkWx2t81qeeVebRZzZ5-kX5gsXLOyBdaFf_-mJEPjd2TcWlzdtTzaXTI64Oi0fipAAy8fFikMua-J4yC4HE2ZT81Y8-Zgzmok5CUUReYIoTz-YVLN-Xsr2cr3Qb4Ghr09xIqYy4TLt1JFu0oLYY1EP3zJwsz_OpLpkq1POkmJzMIE1usItFQ7IhY4ZDmNWFGU6Tj-s9WYfgeU957DENW1JOhsCA5OiHR4uLIsrYAWjeQq6MAZpxKzbwS1pYN_Hy9H1fv82YrmhBdUlqHtU65OsAr4Mwc5dpZLhFA1VEsecuGzdkMfLFbIJu8mvj0S5UG2qjrjucL02Y4Rld-TD1QkjJzpcuaNHPslTBY0DBmkxifR6ukw2O0lSnAljcnvY-UgToG56ZynJ8iSbugitot-iVnQTRNVNWpkp-gaXp3AH6JOymPxjBteDS9-pJspKj0cnlGcheYUUU4bWlo4SSdUg-g-P3IF9G0oKa2CQjWvEvlxZdE9W\" rel=\"nofollow\" target=\"_blank\">www.scynexis.com<\/a><strong>.<\/strong><\/p>\n<p>\n        <strong><br \/>\n          <u>CONTACT<\/u><br \/>\n        <\/strong><br \/>\n        <strong>:<\/strong><br \/>\n        <br \/>\n        <strong>Investor<\/strong>\u00a0<strong>Relations<\/strong><br \/>LifeSci Advisors<\/p>\n<p>John Fraunces<br \/>T: 917-355-2395<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mb587KYlQ1E8Wpp6V5nr0Tf8wGnu1RaHyHCRT8pqME1k_onmy2C_-EmOCMFBoNmLfvb6_ckPKdUD6Ae-Q52n26g8n6NIyocs27lYi5mPre0VKmCN11OHyMP59yA3XxQh\" rel=\"nofollow\" target=\"_blank\">jfraunces@lifesciadvisors.com<\/a><\/p>\n<p>Source: Scynexis<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWJlOGYzMzYtNDZjMi00YzczLWEwOGEtNjAwMTY2ZmI1ZmIwLTUwMDA3MDcxOC0yMDI2LTA1LTA3LWVu\/tiny\/Scynexis-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (Nasdaq: SCYX) (\u201cSCYNEXIS\u201d or the \u201cCompany\u201d), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company\u2019s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee\u2019s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted pursuant to SCYNEXIS\u2019 2015 Inducement Award Plan, as amended, which was adopted by the Company\u2019s Board of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-959412","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (Nasdaq: SCYX) (\u201cSCYNEXIS\u201d or the \u201cCompany\u201d), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company\u2019s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee\u2019s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted pursuant to SCYNEXIS\u2019 2015 Inducement Award Plan, as amended, which was adopted by the Company\u2019s Board of &hellip; Continue reading &quot;SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T01:18:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-05-07T01:18:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":387,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==\",\"datePublished\":\"2026-05-07T01:18:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (Nasdaq: SCYX) (\u201cSCYNEXIS\u201d or the \u201cCompany\u201d), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company\u2019s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee\u2019s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted pursuant to SCYNEXIS\u2019 2015 Inducement Award Plan, as amended, which was adopted by the Company\u2019s Board of &hellip; Continue reading \"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-07T01:18:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-05-07T01:18:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/"},"wordCount":387,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/","name":"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==","datePublished":"2026-05-07T01:18:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTExOCM3NTg5MjIzIzUwMDA3MDcxOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=959412"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=959412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=959412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=959412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}